Nivolumab conferred excellent survival outcomes and durable remissions in patients with advanced melanoma, according to results of a multisite study.
MRV Research
Genomic testing refined accuracy of melanoma risk prediction
Combining test data for melanocortin-1 receptor gene variants and common genomic variants with nongenetic screening resulted in better melanoma risk prediction, Ann Cust, Ph.D., reported at the annual meeting of the American Society of Preventive Oncology.
Immunotherapy, BRAF inhibitor sequence affected outcomes in metastatic melanoma
Prior treatment with immunotherapy did not limit response to BRAF inhibitors among patients with metastatic melanoma, according to results of a retrospective study.
However, patients who underwent initial treatment with BRAF inhibitors and subsequently received immunotherapy with ipilimumab (Yervoy, Bristol-Myers Squibb) demonstrated poorer outcomes, results showed.
Amgen vaccine triggers immune response in advanced melanoma -study
An experimental Amgen Inc cancer vaccine used to treat advanced melanoma, the deadliest form of skin cancer, proved effective in a late-stage study in shrinking tumors in a way that suggests the drug triggered the intended systemic immune response, according to data presented on Friday.